This question is a complex one, as both companies have their own strengths and weaknesses. Krystal Biotech is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare diseases. Their focus is on developing gene therapies, particularly for patients with rare genetic disorders.
Net Margins Return on Equity Return on Assets Krystal Biotech 63.73% 1.99% 1.87% Turnstone Biologics N/A -85.18% -72.25% Earnings and Valuation Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $166.23 million 31.39 $10.93 million $1.87 97.72 Turnstone Biologics $19.31 million 0.81 -$55.20 million ($10.14) -0.07 This table compares Krystal Biotech and Turnstone Biologics”s top-line revenue, earnings per share and valuation. Krystal Biotech has higher revenue and earnings than Turnstone Biologics. Turnstone Biologics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Analyst Ratings
com.
Summary Krystal Biotech beats Turnstone Biologics on 10 of the 13 factors compared between the two stocks. About Krystal Biotech (Get Free Report) Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
Solid tumors are a significant health concern, affecting millions of people worldwide. Turnstone Biologics is committed to developing innovative and effective therapies that can improve the lives of patients battling these challenging diseases. The company’s research and development efforts are focused on identifying and validating novel targets for cancer treatment.
Receive News & Ratings for Krystal Biotech Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Krystal Biotech and related companies with MarketBeat.com’s FREE daily email newsletter.
news is a contributor at WhySkin. We are committed to providing well-researched, accurate, and valuable content to our readers.
